首页> Practical radiation oncology> Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?

Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?

导出 OA

翻译打印收藏纠错

第一作者： Georgios,Ntentas

第一单位： Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. Electronic address: georgios.ntentas@ndph.ox.ac.uk.

作者： Georgios,Ntentas ^[1] ; Katerina,Dedeckova ^[2] ; Michal,Andrlik ^[2] ; Marianne C,Aznar ^[3] ; Ben,George ^[4] ; Jiří,Kubeš ^[2] ; Sarah C,Darby ^[5] ; David J,Cutter ^[6]

作者单位： Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. Electronic address: georgios.ntentas@ndph.ox.ac.uk. ^[1] Proton Therapy Center Czech s.r.o., Prague, Czech Republic. ^[2] Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom. ^[3] CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom. ^[4] Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. ^[5] Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. ^[6]